{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:43:03Z","timestamp":1765284183191,"version":"3.46.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_sjpain-2019-0114_s_001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>In the Western world, it has become clear that we are facing a crisis of overuse, abuse and improperly prescribed use of opioids. As part of the ongoing discussion on opioid use, the use and prescription of tramadol have been addressed in recent years. A significant portion of this discussion should adequately address the risk factors for the use of weak opioid products such as tramadol. The risk factors which characterise the long-term tramadol use are still incompletely understood. Thus, we aimed to describe the characteristics of Danish patients using tramadol in more detail, under different scenarios and determinants of subsequent usage patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2019-0114_s_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide cohort study to identify individuals purchasing tramadol from 01\/01\/2004 to 31\/12\/2015 who are age 16\u2009+\u2009 years old by using data from The Danish National Databases; these databases consist of unique information for all citizens in Denmark. Logistic regression analyses were used to assess the potential risk factors for repeated tramadol use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2019-0114_s_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final cancer-free cohort consisted of N\u2009=\u2009941,839 tramadol users: 54.4% women, with a mean age of 53.2 years. The number of chronic noncancer pain (CNCP) was 430,641 individuals, and 56% of the total third who repeated the use of tramadol with two\u2009+\u2009 purchased prescriptions were CNCP patients. The increased risk of repeated use for CNCP was, among others, associated with: male sex (HR 1.21), age 69\u2013110 (HR 1.72), back\/spine pain men (HR 1.47), women (HR 1.46), spondylopathies (HR 1.24), male osteoporosis (HR 1.22), multimorbid ulcer\/skin (HR 1.28), region of municipality Northern Jutland (HR 1.74), Central Jutland (HR 1.75), number of co-medication 4\u20139 (HR 1.33), dementia (HR 1.27). Factors associated with decreased risk: co-medication ischemic heart disease (HR 0.85), diagnosis headache (HR 0.70), household income highest tertile (HR 0.81), unknown (HR 0.70), single women (HR 0.96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2019-0114_s_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study proved a widespread prescribed use of tramadol in Denmark, and, as know from the literature, weak opioid use may lead to long-term use of high potent opioids, this usage is inappropriate, in general, but especially for the treatment of CNCP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2019-0114_s_005\">\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>When striving to reduce the overuse of opioids, focus on the extensive use of tramadol may be essential. The current study indicates an excessive and not appropriately prescribed use of tramadol among Danish CNCP patients. In addition to being inappropriate, such use may also have an impact on the growing problem of an illicit Internet market for this drug. Thus, the situation must be taken seriously. The current study confirms the recent clinical guideline and the National Recommendations in Denmark, which emphasises the risks of problematic use of tramadol. The research may also be relevant in other comparable countries. Caution must especially be taken with CNCP patients with comorbidities like diabetes, lung disease, dementia, and osteoporosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/sjpain-2019-0114","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T05:03:42Z","timestamp":1568696622000},"page":"109-124","source":"Crossref","is-referenced-by-count":6,"title":["Tramadol prescribed use in general and chronic noncancer pain: a nationwide register-based cohort study of all patients above 16 years"],"prefix":"10.1515","volume":"20","author":[{"given":"Carrinna Aviaja","family":"Hansen","sequence":"first","affiliation":[{"name":"Rigshospitalet Glostrup , Department of Neuroanesthesiology , Glostrup , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin T.","family":"Ernst","sequence":"additional","affiliation":[{"name":"OPEN, Odense Patient Data Explorative Network, University of Southern Denmark , Odense , Denmark"},{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health , University of Southern Denmark , Odense , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stougaard","sequence":"additional","affiliation":[{"name":"OPEN, Odense Patient Data Explorative Network, University of Southern Denmark , Odense , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"OPEN, Odense Patient Data Explorative Network, University of Southern Denmark , Odense , Denmark"},{"name":"Department of Medicine , Holb\u00e6k Hospital , Holb\u00e6k , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"2025120910031653876_j_sjpain-2019-0114_ref_001","doi-asserted-by":"crossref","unstructured":"Allegri N, Mennuni S, Rulli E, Vanacore N, Corli O, Floriani I, De Simone I, Allegri M, Govoni S, Vecchi T, Sandrini G, Liccione D, Biagioli E. Systematic review and meta-analysis on neuropsychological effects of long-term use of opioids in patients with chronic noncancer pain. Pain Pract 2019;19:328\u201343.","DOI":"10.1111\/papr.12741"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_002","doi-asserted-by":"crossref","unstructured":"Birke H, Kurita GP, Sjogren P, Hojsted J, Simonsen MK, Juel K, Ekholm O. Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013. Acta Anaesthesiol Scand 2016;60:623\u201333.","DOI":"10.1111\/aas.12700"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_003","unstructured":"Christensen J, Bilde L, Gustavsson A. Socio-economic consequences of pain-intensive diseases in Denmark. Copenhagen: Danish Institute for Health Services Research. DOI: 978-87-7488-684-6; 2011. Report No.: 3112."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_004","doi-asserted-by":"crossref","unstructured":"DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, Fleming B. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and\/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther 2011;18:216\u201326.","DOI":"10.1097\/MJT.0b013e3181cec307"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_005","doi-asserted-by":"crossref","unstructured":"Harker J, Reid KJ, Bekkering GE, Kellen E, Bala MM, Riemsma R, Worthy G, Misso K, Kleijnen J. Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat 2012;2012:371248.","DOI":"10.1155\/2012\/371248"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_006","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Atluri S, Hansen H, Benyamin RM, Falco FJ, Helm Ii S, Kaye AD, Hirsch JA. Opioids in chronic noncancer pain: have we reached a boiling point yet? Pain Physician 2014;17:E1\u201310.","DOI":"10.36076\/ppj.2014\/17\/E1"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_007","doi-asserted-by":"crossref","unstructured":"Muller AE, Clausen T, Sjogren P, Odsbu I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006\u20132017. Scand J Pain 2019;19:345\u201353.","DOI":"10.1515\/sjpain-2018-0307"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_008","doi-asserted-by":"crossref","unstructured":"Steingrimsdottir OA, Landmark T, Macfarlane GJ, Nielsen CS. Defining chronic pain in epidemiological studies: a systematic review and meta-analysis. Pain 2017;158:2092\u2013107.","DOI":"10.1097\/j.pain.0000000000001009"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_009","unstructured":"The-Danish-Health-Authority, The-Health-Data-Protection-Agency, The-Danish-Medicines-Agency. Kortl\u00e6gning af opioidforbruget i Danmark \u2013 med fokus p\u00e5 patienter med kroniske non-maligne smerter [Mapping opioid consumption in Denmark \u2013 focusing on patients with chronic non-malignant pain]. Copenhagen: Sundhedsstyrelsen [The Danish Health Authority]; 2016 [updated 08-2016. Available from: https:\/\/www.sst.dk\/da\/Feeds\/~\/media\/69913B827BAA4850A9A70E0CF76CB305.ashx."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_010","doi-asserted-by":"crossref","unstructured":"Vargas-Schaffer G, Cogan J. Attitudes toward opioids and risk of misuse\/abuse in patients with chronic noncancer pain receiving long-term opioid therapy. Pain Med 2018;19:319\u201327.","DOI":"10.1093\/pm\/pnw338"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_011","doi-asserted-by":"crossref","unstructured":"Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL. Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend 2013;129:116\u201324.","DOI":"10.1016\/j.drugalcdep.2012.09.018"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_012","doi-asserted-by":"crossref","unstructured":"Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain 2014;30: 557\u201364.","DOI":"10.1097\/AJP.0000000000000021"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_013","doi-asserted-by":"crossref","unstructured":"Hojsted J, Ekholm O, Kurita GP, Juel K, Sjogren P. Addictive behaviors related to opioid use for chronic pain: a population-based study. Pain 2013;154:2677\u201383.","DOI":"10.1016\/j.pain.2013.07.046"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_014","doi-asserted-by":"crossref","unstructured":"Skurtveit S, Furu K, Borchgrevink P, Handal M, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain 2011;152:1555\u201361.","DOI":"10.1016\/j.pain.2011.02.045"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_015","doi-asserted-by":"crossref","unstructured":"Busse JW, Mahmood H, Maqbool B, Maqbool A, Zahran A, Alwosaibai A, Alshaqaq E, Persaud N, Cooper L, Carol A, Sumpton J, McGinnis E, Rosenbaum D, Lidster N, Buckley DN. Characteristics of patients receiving long-term opioid therapy for chronic noncancer pain: a cross-sectional survey of patients attending the Pain Management Centre at Hamilton General Hospital, Hamilton, Ontario. CMAJ Open 2015;3:E324\u201330.","DOI":"10.9778\/cmajo.20140126"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_016","unstructured":"The-Danish-Health-Authority. Opioidbehandling af kroniske non-maligne smerter, National Klinisk Retningslinje [Opioid treatment of chronic non-malignant pain, National Clinical Guideline]. Copenhagen: Sundhedsstyrelsen; 2018 [updated 2018-12; cited 2019 02-23]. Dec. 2018:[Available from: https:\/\/www.sst.dk\/da\/udgivelser\/2018\/~\/media\/1DC940E1B0C94614B5C15782D6869975.ashx."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_017","unstructured":"The-Danish-Health-Authority. National clinical guideline on opioid treatment of chronic non-malignant pain. Quick guide. Copenhagen: Sundhedsstyrelsen; 2018 [updated Dec. 2018; cited 2019 02-23]. Available from: https:\/\/www.sst.dk\/da\/udgivelser\/2018\/~\/media\/2C475D632B164AADB3C1F612BE1331B2.ashx."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_018","unstructured":"Statistics-Denmark. Danmark i tal 2019 [Denmark in numbers 2019] 2019 [Available from: https:\/\/www.dst.dk\/Site\/Dst\/Udgivelser\/GetPubFile.aspx?id=28921&sid=dkital2019."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_019","unstructured":"Statistics, Denmark. StatBank Denmark: Statistics Denmark; 2016 [Available from: http:\/\/www.statistikbanken.dk\/statbank5a\/default.asp?w=1280."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_020","doi-asserted-by":"crossref","unstructured":"Andrews JS, Wu N, Chen SY, Yu X, Peng X, Novick D. Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care. J Pain Res 2013;6:825\u201335.","DOI":"10.2147\/JPR.S50323"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_021","unstructured":"The-Danish-Health-Authority. Den Nationale Rekommandationsliste [The National Recommendation List]. Sundhedsstyrelsen [Danish-Health-Authority]; 2018 [Available from: https:\/\/www.sst.dk\/da\/rationel-farmakoterapi\/rekommandationsliste."},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_022","doi-asserted-by":"crossref","unstructured":"Hauser W, Bernardy K, Maier C. [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]. Schmerz 2015;29:96\u2013108.","DOI":"10.1007\/s00482-014-1452-0"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_023","doi-asserted-by":"crossref","unstructured":"Welsch P, Sommer C, Schiltenwolf M, Hauser W. [Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week\u2019s duration]. Schmerz 2015;29:85\u201395.","DOI":"10.1007\/s00482-014-1436-0"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_024","doi-asserted-by":"crossref","unstructured":"Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, side effects, and serotonin syndrome: a review. Pain Physician 2015;18:395\u2013400.","DOI":"10.36076\/ppj.2015\/18\/395"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_025","doi-asserted-by":"crossref","unstructured":"Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med 2015;175: 186\u201393.","DOI":"10.1001\/jamainternmed.2014.6512"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_026","doi-asserted-by":"crossref","unstructured":"Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, Sharma S, Kolahdooz F, Straube S. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2017;10:Cd012509.","DOI":"10.1002\/14651858.CD012509"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_027","doi-asserted-by":"crossref","unstructured":"Hansen CA, Abrahamsen B. Predictors of long-term opioid use among chronic nonmalignant pain patients: a register-based national open cohort study. Scand J Pain 2016;12:120.","DOI":"10.1016\/j.sjpain.2016.05.012"},{"key":"2025120910031653876_j_sjpain-2019-0114_ref_028","doi-asserted-by":"crossref","unstructured":"Wister A, Kendig H, Mitchell B, Fyffe I, Loh V. Multimorbidity, health and aging in Canada and Australia: a tale of two countries. BMC Geriatr 2016;16:163.","DOI":"10.1186\/s12877-016-0341-z"}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/sjpain\/20\/1\/article-p109.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2019-0114\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2019-0114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:40:27Z","timestamp":1765284027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2019-0114\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,12]]},"published-print":{"date-parts":[[2019,12,18]]}},"alternative-id":["10.1515\/sjpain-2019-0114"],"URL":"https:\/\/doi.org\/10.1515\/sjpain-2019-0114","relation":{},"ISSN":["1877-8879","1877-8860"],"issn-type":[{"type":"electronic","value":"1877-8879"},{"type":"print","value":"1877-8860"}],"subject":[],"published":{"date-parts":[[2019,9,17]]}}}